Myriad wins diagnostics IP case

Myriad Genetics ($MYGN) scored a win with a federal court's ruling that the company's claims on genes that predict risk of breast and ovarian cancers can be patented, bringing a close to the company's lengthy battle to secure its intellectual property and encouraging biotechs with heavy interests in genetic research. Report

Like what you're reading?
Click here to get more news like this delivered to your inbox every day >>

Suggested Articles

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports.

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.